Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with...
Saved in:
| Published in: | Therapeutic Advances in Medical Oncology Vol. 9; no. 9; pp. 589 - 597 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Book Review Journal Article |
| Language: | English |
| Published: |
London, England
SAGE Publications
01-09-2017
Sage Publications Ltd |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with prognostic implications. Moreover, recent data recognizing the distinct biology and therapeutic vulnerabilities of different KRAS subgroups have allowed us to explore different treatment approaches. Small molecules that selectively inhibit KRAS G12C or use of immune checkpoint inhibitors based on co-mutation status are some examples which anticipate that personalized treatment for this challenging disease is finally on the horizon. |
|---|---|
| AbstractList | KRAS
mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed
KRAS
mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with prognostic implications. Moreover, recent data recognizing the distinct biology and therapeutic vulnerabilities of different
KRAS
subgroups have allowed us to explore different treatment approaches. Small molecules that selectively inhibit
KRAS
G12C or use of immune checkpoint inhibitors based on co-mutation status are some examples which anticipate that personalized treatment for this challenging disease is finally on the horizon. KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with prognostic implications. Moreover, recent data recognizing the distinct biology and therapeutic vulnerabilities of different KRAS subgroups have allowed us to explore different treatment approaches. Small molecules that selectively inhibit KRAS G12C or use of immune checkpoint inhibitors based on co-mutation status are some examples which anticipate that personalized treatment for this challenging disease is finally on the horizon. mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed mutation as a unique disease. The recent widespread use of comprehensive genomic profiling has identified different subgroups with prognostic implications. Moreover, recent data recognizing the distinct biology and therapeutic vulnerabilities of different subgroups have allowed us to explore different treatment approaches. Small molecules that selectively inhibit G12C or use of immune checkpoint inhibitors based on co-mutation status are some examples which anticipate that personalized treatment for this challenging disease is finally on the horizon. |
| Author | López-Ríos, Fernando Rosa-Rosa, Juan Manuel Garrido, Pilar Olmedo, María Eugenia Gómez, Ana Paz Ares, Luis Palacios, José |
| Author_xml | – sequence: 1 givenname: Pilar surname: Garrido fullname: Garrido, Pilar email: pilargarridol@gmail.com organization: Head of Thoracic Tumor Unit, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Facultad de Medicina. Universidad de Alcalá (IRYCIS) Carretera Colmenar Viejo KM 9100, 28034 Madrid, Spain – sequence: 2 givenname: María Eugenia surname: Olmedo fullname: Olmedo, María Eugenia organization: Medical Oncology Department, Hospital Universitario Ramón y Cajal. Facultad de Medicina. Universidad de Alcalá (IRYCIS), Madrid, Spain – sequence: 3 givenname: Ana surname: Gómez fullname: Gómez, Ana organization: Medical Oncology Department, Hospital Universitario Ramón y Cajal. Facultad de Medicina. Universidad de Alcalá (IRYCIS), Madrid, Spain – sequence: 4 givenname: Luis surname: Paz Ares fullname: Paz Ares, Luis organization: Centro de Investigaciones Biomédicas en Red en Cáncer (CIBER-ONC), Madrid, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Universidad Complutense and Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain – sequence: 5 givenname: Fernando surname: López-Ríos fullname: López-Ríos, Fernando organization: Centro de Investigaciones Biomédicas en Red en Cáncer (CIBER-ONC), Madrid, Spain Hospital Universitario HM Sanchinarro C/ Oña, 10. 28050 Madrid, España – sequence: 6 givenname: Juan Manuel surname: Rosa-Rosa fullname: Rosa-Rosa, Juan Manuel organization: Centro de Investigaciones Biomédicas en Red en Cáncer (CIBER-ONC), Madrid, Spain – sequence: 7 givenname: José surname: Palacios fullname: Palacios, José organization: Centro de Investigaciones Biomédicas en Red en Cáncer (CIBER-ONC), Madrid, Spain Servicio de Anatomía Patológica, Hospital Universitario Ramón y Cajal, Universidad de Alcalá (IRYCIS), Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29081842$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1LHEEQhpug-LHJPScZyMXLmP6eag8BWUwMWRTi3pvantp1ZLZHp2cE_729rFEjeGi66Hrqrap-D9lO7CIx9lXwEyGq6ruoDIDSPMfCgXSf2MHmqQRl3M6beJ8dpnTLubXa8j22Lx0HAVoesPN5Tzg0cVX8-Xt2Xa7HAeNQXF5PZ9PTosWB0lDQQ1NTDFRgrIvQNrEJ2Bahi4nux00ifWa7S2wTfXm-J2z-83w-vShnV79-T89mZdBWDiUsNZJdGGcgLHAJmI-u1QKQlFQSbBUg1M7IWmpjAC1oo6wO2iEFF9SE_djK3o2LNdWB4tBj6-_6Zo39o--w8f9nYnPjV92DN8ZqAJEFjp8F-i6Pnga_blKgtsVI3Zi8cKaqbAX5Uyfs2zv0thv7mLfzUmmprOWgM8W3VOi7lHpavgwjuN9Y5N9blEuO3i7xUvDPkwyUWyDhil67fij4BI5Lmko |
| CitedBy_id | crossref_primary_10_18632_oncotarget_25668 crossref_primary_10_1186_s12967_023_03901_5 crossref_primary_10_1016_j_ebiom_2019_02_049 crossref_primary_10_1016_j_phymed_2019_153000 crossref_primary_10_3390_ijms23169391 crossref_primary_10_1097_CAD_0000000000001176 crossref_primary_10_1073_pnas_2026104118 crossref_primary_10_3390_cancers13246332 crossref_primary_10_1038_s41598_020_59744_3 crossref_primary_10_1038_s42003_021_01898_5 crossref_primary_10_2147_CMAR_S254139 crossref_primary_10_3390_curroncol30070476 crossref_primary_10_1016_j_ejca_2020_06_023 crossref_primary_10_1016_j_eclinm_2021_100797 crossref_primary_10_3390_cancers14051321 crossref_primary_10_1200_JCO_20_00744 crossref_primary_10_1021_acs_analchem_3c05500 crossref_primary_10_2174_0929867326666190222183219 crossref_primary_10_1111_jcmm_17640 crossref_primary_10_1016_j_jmoldx_2020_02_011 crossref_primary_10_1007_s40265_024_02030_7 crossref_primary_10_1186_s12943_019_0939_9 crossref_primary_10_3390_pharmaceutics15041252 crossref_primary_10_1111_1759_7714_13542 crossref_primary_10_1186_s12575_018_0084_7 crossref_primary_10_3389_fonc_2021_792635 |
| Cites_doi | 10.1038/nature13385 10.1016/j.jtho.2016.11.1312 10.1038/nature10937 10.1093/annonc/mdv072 10.7314/APJCP.2015.16.10.4439 10.1016/j.ccr.2009.03.022 10.1016/j.jtho.2016.11.2218 10.1200/JCO.2007.12.6953 10.1016/S1470-2045(12)70489-8 10.1016/S0140-6736(16)00004-0 10.1158/1078-0432.CCR-16-2554 10.1016/j.jtho.2015.11.010 10.1016/j.cell.2012.08.029 10.1093/jnci/djr523 10.1016/j.lungcan.2012.06.005 10.1158/0008-5472.CAN-15-2580 10.1158/1078-0432.CCR-14-3112 10.1158/1541-7786.MCR-15-0456 10.1038/bjc.2015.215 10.1038/onc.2015.375 10.1016/j.jtho.2016.11.402 10.1016/j.critrevonc.2016.12.005 10.1101/gad.1950610 10.1183/09031936.00097311 10.1016/j.cllc.2015.12.010 10.1158/2159-8290.CD-14-1236 10.1093/annonc/mdq680 10.1158/2159-8290.CD-16-0095 10.1038/nature07423 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E 10.1038/bjc.2015.327 10.18632/oncotarget.4711 10.1097/JTO.0000000000000432 10.1002/cncr.26311 10.1200/JCO.2012.48.1390 10.1158/0008-5472.CAN-15-1439 10.1200/JCO.2001.19.2.448 10.1200/jco.2010.28.15_suppl.7008 10.1016/j.lungcan.2013.03.019 10.1001/jamaoncol.2016.0405 10.1158/0008-5472.CAN-16-0808 10.1038/nrd.2016.139 10.1158/1078-0432.CCR-08-0646 10.1097/JTO.0000000000000305 10.1586/17476348.2016.1115349 10.1126/science.aad6204 10.1158/2159-8290.CD-15-1105 10.1172/JCI82720 10.18632/oncotarget.5019 10.18632/oncotarget.7080 10.1097/JTO.0000000000000687 10.1093/annonc/mdn503 10.1158/1078-0432.CCR-15-2603 10.2217/fon.15.273 10.1158/2159-8290.CD-16-0092 10.1038/nature13898 10.1038/bjc.2016.182 10.1097/JTO.0000000000000266 |
| ContentType | Book Review Journal Article |
| Copyright | The Author(s), 2017 The Author(s), 2017. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s), 2017 2017 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| Copyright_xml | – notice: The Author(s), 2017 – notice: The Author(s), 2017. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s), 2017 2017 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| DBID | AFRWT NPM AAYXX CITATION 3V. 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1177/1758834017719829 |
| DatabaseName | Sage Journals GOLD Open Access 2024 PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1758-8359 |
| EndPage | 597 |
| ExternalDocumentID | 10_1177_1758834017719829 29081842 10.1177_1758834017719829 |
| Genre | Journal Article Review |
| GroupedDBID | --- -MK -TM 01A 0R~ 29Q 31X 4.4 53G 54M 5VS 7X7 8FI 8FJ AABMB AADTT AADUE AAJQC AAQDB AARDL AARIX AATBZ ABAFQ ABAWP ABEIX ABFWQ ABJIS ABKRH ABQXT ABRHV ABUWG ABVFX ACARO ACDSZ ACDXX ACGFS ACGZU ACOFE ACROE ACSBE ACSIQ ACUIR ADBBV ADOGD ADZZY AENEX AEQLS AERKM AEUHG AEUIJ AEWDL AEWHI AEXNY AFCOW AFEET AFKRA AFKRG AFRWT AFUIA AGNHF AHHFK AJUZI ALIPV ALJHS ALMA_UNASSIGNED_HOLDINGS AOIJS ARTOV ASPBG AUTPY AUVAJ AVWKF AYAKG AZFZN B8M B8Z BAWUL BCNDV BDDNI BENPR BKSCU BPHCQ BSEHC BVXVI CAG CCPQU CDWPY CFDXU COF DC- DC. DIK DOPDO DV7 EBS EJD EMOBN F5P FEDTE FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 HF~ HMCUK HVGLF HYE HZ~ J8X JCYGO K.F M4V N9A O9- OK1 P.B PIMPY PQQKQ ROL RPM S01 SFC SGV UKHRP ZONMY ZPPRI ZRKOI ZSSAH H13 NPM AAYXX CITATION 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-8f4ae6b5958cbaf8aaf84d3b8ae3232867c8cd952d24558a6845364c49aec9c3 |
| IEDL.DBID | RPM |
| ISSN | 1758-8359 1758-8340 |
| IngestDate | Tue Sep 17 20:53:13 EDT 2024 Thu Oct 24 22:39:39 EDT 2024 Thu Oct 10 17:03:58 EDT 2024 Wed Oct 23 14:20:14 EDT 2024 Wed Oct 16 01:00:17 EDT 2024 Tue Jul 16 20:51:55 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | non-small cell lung cancer genomic profiling KRAS prognostic factor predictive factor |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-8f4ae6b5958cbaf8aaf84d3b8ae3232867c8cd952d24558a6845364c49aec9c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564881/ |
| PMID | 29081842 |
| PQID | 2342366084 |
| PQPubID | 4450840 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5564881 proquest_miscellaneous_1957767888 proquest_journals_2342366084 crossref_primary_10_1177_1758834017719829 pubmed_primary_29081842 sage_journals_10_1177_1758834017719829 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: England – name: London – name: Sage UK: London, England |
| PublicationTitle | Therapeutic Advances in Medical Oncology |
| PublicationTitleAlternate | Ther Adv Med Oncol |
| PublicationYear | 2017 |
| Publisher | SAGE Publications Sage Publications Ltd |
| Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd |
| References | Ihle, Byers, Kim 2012; 104 Blumenschein, Smit, Planchard 2015; 26 Rak, Mitsuhashi, Bayko 1995; 55 Guerrero, Casanova, Farre 2000; 60 Tsao, Aviel-Ronen, Ding 2007; 25 Meng, Yuan, Li 2013; 81 Patnaik, Rosen, Tolaney 2016; 6 Wang, Han, Marcar 2017; 77 Calles, Sholl, Rodig 2015; 21 Shepherd, Domerg, Hainaut 2013; 31 Singh, Greninger, Rhodes 2009; 15 Ma, Vataire, Sun 2008; 19 Chen, Cheng, Walton 2012; 483 Calles, Liao, Sholl 2015; 10 Westcott, Halliwill, To 2015; 517 Jänne, Van Den Heuvel, Barlesi; 12 Ying, Zhu, Zhao 2015; 16 Wood, Hensing, Malik 2016; 2 Kim, Shim, Chung 2012; 118 Riely, Kris, Rosenbaum 2008; 14 Brady, McNeill, Judy 2015; 6 Scoccianti, Vesin, Martel 2012; 40 Caiola, Salles, Frapolli 2015; 6 Dong, Zhong, Zhang 2016; 23 Metro, Chiari, Duranti 2012; 78 Schabath, Welsh, Fulp 2016; 35 Renaud, Falcoz, Schaeffer 2015; 113 Schiller, Adak, Feins 2001; 19 Kent, Mendell, Rottapel 2016; 14 Gandara, Leighl, Delord 2017; 12 Langsch, Baumgartner, Haemmig 2016; 76 Janne, Smith, McWalter 2015; 113 Patricelli, Janes, Li 2016; 6 Barlesi, Mazieres, Merlio 2016; 387 Al-Mulla, Milner-White, Going, Birnie 1999; 187 Yu, Sima, Shen 2015; 10 Koyama, Akbay, Li 2016; 76 2014; 511 Capelletti, Wang, Gu 2010; 28 Skoulidis, Elamin, Papadimitrakopoulou 2016; 12 Janne, Shaw, Pereira 2013; 14 Pan, Yang, Zhu 2016; 7 Janne, Mann, Ghiorghiu 2016; 17 Edmonds, Boyd, Moyo 2016; 126 Ding, Getz, Wheeler 2008; 455 Garassino, Marabese, Rusconi 2011; 22 Renaud, Schaeffer, Voegeli 2016; 12 Ricciuti, Leonardi, Metro 2016; 10 Renaud, Seitlinger, Falcoz 2016; 115 Lito, Solomon, Li 2016; 351 Zer, Ding, Lee 2016; 11 Ostrem, Shokat 2016; 15 Kent, Chivukula, Mullendore 2010; 24 Imielinski, Berger, Hammerman 2012; 150 Nadal, Chen, Prensner 2014; 9 Skoulidis, Byers, Diao 2015; 5 Westover, Janne, Gray 2016; 6 Tang, Constanzo, Venkateswaran 2016; 22 Izar, Zhou, Heist 2014; 9 Matikas, Mistriotis, Georgoulias 2017; 110 19477428 - Cancer Cell. 2009 Jun 2;15(6):489-500 26028111 - Asian Pac J Cancer Prev. 2015;16(10):4439-45 28202526 - Cancer Res. 2017 Apr 15;77(8):2018-2028 21720997 - Cancer. 2012 Feb 1;118(3):729-39 11208838 - J Clin Oncol. 2001 Jan 15;19(2):448-57 18024870 - J Clin Oncol. 2007 Nov 20;25(33):5240-7 11118062 - Cancer Res. 2000 Dec 1;60(23):6750-6 10398103 - J Pathol. 1999 Mar;187(4):433-8 22247021 - J Natl Cancer Inst. 2012 Feb 8;104(3):228-39 26616848 - Future Oncol. 2016 Jan;12(1):59-70 21169473 - Ann Oncol. 2011 Jan;22(1):235-7 22425996 - Nature. 2012 Mar 18;483(7391):613-7 7553632 - Cancer Res. 1995 Oct 15;55(20):4575-80 18948947 - Nature. 2008 Oct 23;455(7216):1069-75 26739882 - Cancer Discov. 2016 Mar;6(3):316-29 25415430 - J Thorac Oncol. 2015 Mar;10(3):431-7 23630215 - J Clin Oncol. 2013 Jun 10;31(17 ):2173-81 27217383 - Cancer Discov. 2016 Jul;6(7):740-53 26833127 - Cancer Res. 2016 Mar 1;76(5):999-1008 26840022 - Oncotarget. 2016 Feb 16;7(7):8373-88 27876675 - J Thorac Oncol. 2017 Mar;12 (3):556-566 28039262 - Clin Cancer Res. 2017 Jun 15;23 (12 ):3012-3024 25722381 - Ann Oncol. 2015 May;26(5):894-901 27199349 - Cancer Res. 2016 Jul 15;76(14 ):4160-9 21159816 - Genes Dev. 2010 Dec 15;24(24):2754-9 26841430 - Science. 2016 Feb 5;351(6273):604-8 26951837 - Cancer Discov. 2016 Mar;6(3):233-4 23200175 - Lancet Oncol. 2013 Jan;14 (1):38-47 25079552 - Nature. 2014 Jul 31;511(7511):543-50 26477306 - Oncogene. 2016 Jun 16;35(24):3209-16 25363767 - Nature. 2015 Jan 22;517(7535):489-92 26837474 - Clin Lung Cancer. 2016 Mar;17 (2):e1-4 26353932 - Oncotarget. 2015 Oct 6;6(30):30072-87 26749487 - J Thorac Oncol. 2016 Mar;11(3):312-23 26777916 - Lancet. 2016 Apr 2;387(10026):1415-1426 26473645 - J Thorac Oncol. 2015 Dec;10 (12 ):1726-35 28109399 - Crit Rev Oncol Hematol. 2017 Feb;110:1-12 25170638 - J Thorac Oncol. 2014 Oct;9(10 ):1513-22 18794081 - Clin Cancer Res. 2008 Sep 15;14 (18):5731-4 26069186 - Cancer Discov. 2015 Aug;5(8):860-77 27469033 - Nat Rev Drug Discov. 2016 Nov;15(11):771-785 22980975 - Cell. 2012 Sep 14;150(6):1107-20 25122432 - J Thorac Oncol. 2014 Sep;9(9):1363-9 22267755 - Eur Respir J. 2012 Jul;40(1):177-84 26372703 - Br J Cancer. 2015 Oct 20;113(8):1206-15 22770374 - Lung Cancer. 2012 Oct;78(1):81-6 26714748 - Expert Rev Respir Med. 2016;10(1):53-68 27336603 - Br J Cancer. 2016 Jul 26;115(3):346-53 26747707 - Mol Cancer Res. 2016 Mar;14 (3):267-77 23608713 - Lung Cancer. 2013 Jul;81(1):1-10 26657862 - J Clin Invest. 2016 Jan;126(1):349-64 27100819 - JAMA Oncol. 2016 Jun 1;2(6):805-12 27220963 - Clin Cancer Res. 2016 Dec 1;22(23 ):5851-5863 26125448 - Br J Cancer. 2015 Jul 14;113(2):199-203 25737507 - Clin Cancer Res. 2015 Jun 15;21(12):2851-60 26471290 - Oncotarget. 2015 Oct 6;6(30):30287-94 bibr27-1758834017719829 bibr60-1758834017719829 bibr52-1758834017719829 bibr19-1758834017719829 bibr35-1758834017719829 bibr36-1758834017719829 bibr18-1758834017719829 bibr44-1758834017719829 bibr51-1758834017719829 bibr5-1758834017719829 bibr53-1758834017719829 bibr45-1758834017719829 bibr50-1758834017719829 bibr37-1758834017719829 bibr54-1758834017719829 bibr6-1758834017719829 bibr28-1758834017719829 bibr3-1758834017719829 bibr42-1758834017719829 bibr29-1758834017719829 bibr55-1758834017719829 bibr21-1758834017719829 bibr39-1758834017719829 bibr47-1758834017719829 bibr34-1758834017719829 bibr8-1758834017719829 bibr26-1758834017719829 bibr13-1758834017719829 bibr22-1758834017719829 Guerrero S (bibr10-1758834017719829) 2000; 60 Rak J (bibr11-1758834017719829) 1995; 55 bibr48-1758834017719829 bibr49-1758834017719829 bibr1-1758834017719829 bibr31-1758834017719829 bibr57-1758834017719829 bibr14-1758834017719829 bibr15-1758834017719829 bibr58-1758834017719829 bibr23-1758834017719829 bibr32-1758834017719829 Janne PA (bibr46-1758834017719829) 2016; 17 bibr2-1758834017719829 bibr24-1758834017719829 bibr41-1758834017719829 bibr59-1758834017719829 bibr20-1758834017719829 bibr38-1758834017719829 Ma X (bibr16-1758834017719829) 2008; 19 bibr33-1758834017719829 bibr12-1758834017719829 bibr25-1758834017719829 bibr7-1758834017719829 bibr40-1758834017719829 bibr4-1758834017719829 bibr9-1758834017719829 bibr43-1758834017719829 bibr17-1758834017719829 bibr30-1758834017719829 bibr56-1758834017719829 |
| References_xml | – volume: 10 start-page: 1726 year: 2015 end-page: 1735 article-title: Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer publication-title: J Thorac Oncol contributor: fullname: Sholl – volume: 118 start-page: 729 year: 2012 end-page: 739 article-title: Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement publication-title: Cancer contributor: fullname: Chung – volume: 12 start-page: 59 year: 2016 end-page: 70 article-title: Impact of EGFR mutations and KRAS amino acid sdubstitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer publication-title: Future Oncol contributor: fullname: Voegeli – volume: 19 start-page: 448 year: 2001 end-page: 457 article-title: Lack of prognostic significance of p53 and K-Ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy publication-title: J Clin Oncol contributor: fullname: Feins – volume: 22 start-page: 5851 year: 2016 end-page: 5863 article-title: Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer publication-title: Clin Cancer Res contributor: fullname: Venkateswaran – volume: 126 start-page: 349 year: 2016 end-page: 364 article-title: MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer publication-title: J Clin Invest contributor: fullname: Moyo – volume: 387 start-page: 1415 year: 2016 end-page: 1426 article-title: Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) publication-title: Lancet contributor: fullname: Merlio – volume: 60 start-page: 6750 year: 2000 end-page: 6756 article-title: K-RAS codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression publication-title: Cancer Res contributor: fullname: Farre – volume: 26 start-page: 894 year: 2015 end-page: 901 article-title: A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)dagger publication-title: Ann Oncol contributor: fullname: Planchard – volume: 10 start-page: 431 year: 2015 end-page: 437 article-title: Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas publication-title: J Thorac Oncol contributor: fullname: Shen – volume: 16 start-page: 4439 year: 2015 end-page: 4445 article-title: KRAS mutation as a biomarker for survival in patients with non-small cell lung cancer, a meta-analysis of 12 randomized trials publication-title: Asian Pac J Cancer Prev contributor: fullname: Zhao – volume: 22 start-page: 235 year: 2011 end-page: 237 article-title: Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer publication-title: Ann Oncol contributor: fullname: Rusconi – volume: 115 start-page: 346 year: 2016 end-page: 353 article-title: Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery publication-title: Br J Cancer contributor: fullname: Falcoz – volume: 14 start-page: 267 year: 2016 end-page: 277 article-title: Transcriptional regulation of miR-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1 publication-title: Mol Cancer Res contributor: fullname: Rottapel – volume: 6 start-page: 233 year: 2016 end-page: 234 article-title: Progress on Covalent Inhibition of KRAS(G12C) publication-title: Cancer Discov contributor: fullname: Gray – volume: 81 start-page: 1 year: 2013 end-page: 10 article-title: Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis publication-title: Lung Cancer contributor: fullname: Li – volume: 9 start-page: 1513 year: 2014 end-page: 1522 article-title: KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma publication-title: J Thorac Oncol contributor: fullname: Prensner – volume: 21 start-page: 2851 year: 2015 end-page: 2860 article-title: Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma publication-title: Clin Cancer Res contributor: fullname: Rodig – volume: 11 start-page: 312 year: 2016 end-page: 323 article-title: Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors publication-title: J Thorac Oncol contributor: fullname: Lee – volume: 2 start-page: 805 year: 2016 end-page: 812 article-title: Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review publication-title: JAMA Oncol contributor: fullname: Malik – volume: 6 start-page: 30072 year: 2015 end-page: 30087 article-title: Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells publication-title: Oncotarget contributor: fullname: Frapolli – volume: 15 start-page: 489 year: 2009 end-page: 500 article-title: A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival publication-title: Cancer Cell contributor: fullname: Rhodes – volume: 5 start-page: 860 year: 2015 end-page: 877 article-title: Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities publication-title: Cancer Discov contributor: fullname: Diao – volume: 150 start-page: 1107 year: 2012 end-page: 1120 article-title: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing publication-title: Cell contributor: fullname: Hammerman – volume: 351 start-page: 604 year: 2016 end-page: 608 article-title: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism publication-title: Science contributor: fullname: Li – volume: 6 start-page: 316 year: 2016 end-page: 329 article-title: Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state publication-title: Cancer Discov contributor: fullname: Li – volume: 55 start-page: 4575 year: 1995 end-page: 4580 article-title: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis publication-title: Cancer Res contributor: fullname: Bayko – volume: 25 start-page: 5240 year: 2007 end-page: 5247 article-title: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Ding – volume: 78 start-page: 81 year: 2012 end-page: 86 article-title: Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype publication-title: Lung Cancer contributor: fullname: Duranti – volume: 10 start-page: 53 year: 2016 end-page: 68 article-title: Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications publication-title: Expert Rev Respir Med contributor: fullname: Metro – volume: 24 start-page: 2754 year: 2010 end-page: 2759 article-title: Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway publication-title: Genes Dev contributor: fullname: Mullendore – volume: 76 start-page: 999 year: 2016 end-page: 1008 article-title: STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment publication-title: Cancer Res contributor: fullname: Li – volume: 15 start-page: 771 year: 2016 end-page: 785 article-title: Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design publication-title: Nat Rev Drug Discov contributor: fullname: Shokat – volume: 104 start-page: 228 year: 2012 end-page: 239 article-title: Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome publication-title: J Natl Cancer Inst contributor: fullname: Kim – volume: 17 start-page: e1 year: 2016 end-page: e4 article-title: Study design and rationale for a randomized, placebo-controlled, double-blind study to assess the efficacy and safety of selumetinib in combination with docetaxel as second-line treatment in patients with KRAS-mutant advanced non-small cell lung cancer (SELECT-1) publication-title: Clin Lung Cancer contributor: fullname: Ghiorghiu – volume: 6 start-page: 740 year: 2016 end-page: 753 article-title: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors publication-title: Cancer Discov contributor: fullname: Tolaney – volume: 19 start-page: viii61 year: 2008 end-page: viii62 article-title: TP53 and KRAS Mutations as markers of outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small cell lung cancer (NSCLC): The International Adjuvant Lung Cancer Trial (IALT) biological program publication-title: Ann Oncol contributor: fullname: Sun – volume: 28 start-page: 7008 year: 2010 article-title: Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633 publication-title: J Clin Oncology contributor: fullname: Gu – volume: 40 start-page: 177 year: 2012 end-page: 184 article-title: Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort publication-title: Eur Respir J contributor: fullname: Martel – volume: 12 start-page: S361 year: 2016 end-page: S362 article-title: MA04.07 impact of major co-mutations on the immune contexture and response of KRAS-mutant lung adenocarcinoma to immunotherapy publication-title: J Thorac Oncol contributor: fullname: Papadimitrakopoulou – volume: 455 start-page: 1069 year: 2008 end-page: 1075 article-title: Somatic mutations affect key pathways in lung adenocarcinoma publication-title: Nature contributor: fullname: Wheeler – volume: 76 start-page: 4160 year: 2016 end-page: 4169 article-title: miR-29b mediates NF-kappaB signaling in KRAS-induced non-small cell lung cancers publication-title: Cancer Res contributor: fullname: Haemmig – volume: 12 start-page: S952 end-page: S953 article-title: P2.03b-031 Impact of PD-L1 status on clinical response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC publication-title: J Thorac Oncol contributor: fullname: Barlesi – volume: 6 start-page: 30287 year: 2015 end-page: 30294 article-title: Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy publication-title: Oncotarget contributor: fullname: Judy – volume: 23 start-page: 3012 year: 2016 end-page: 3024 article-title: Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma publication-title: Clin Cancer Res contributor: fullname: Zhang – volume: 35 start-page: 3209 year: 2016 end-page: 3216 article-title: Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma publication-title: Oncogene contributor: fullname: Fulp – volume: 12 start-page: 556 year: 2017 end-page: 566 article-title: A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non-small cell lung cancer publication-title: J Thorac Oncol contributor: fullname: Delord – volume: 187 start-page: 433 year: 1999 end-page: 438 article-title: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression publication-title: J Pathol contributor: fullname: Birnie – volume: 511 start-page: 543 year: 2014 end-page: 550 article-title: Comprehensive molecular profiling of lung adenocarcinoma publication-title: Nature – volume: 31 start-page: 2173 year: 2013 end-page: 2181 article-title: Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy publication-title: J Clin Oncol contributor: fullname: Hainaut – volume: 517 start-page: 489 year: 2015 end-page: 492 article-title: The mutational landscapes of genetic and chemical models of Kras-driven lung cancer publication-title: Nature contributor: fullname: To – volume: 7 start-page: 8373 year: 2016 end-page: 8388 article-title: KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: a meta-analysis of 41 studies publication-title: Oncotarget contributor: fullname: Zhu – volume: 110 start-page: 1 year: 2017 end-page: 12 article-title: Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity publication-title: Crit Rev Oncol Hematol contributor: fullname: Georgoulias – volume: 14 start-page: 38 year: 2013 end-page: 47 article-title: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study publication-title: Lancet Oncology contributor: fullname: Pereira – volume: 113 start-page: 199 year: 2015 end-page: 203 article-title: Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer publication-title: Br J Cancer contributor: fullname: McWalter – volume: 9 start-page: 1363 year: 2014 end-page: 1369 article-title: The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma publication-title: J Thorac Oncol contributor: fullname: Heist – volume: 14 start-page: 5731 year: 2008 end-page: 5734 article-title: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma publication-title: Clin Cancer Res contributor: fullname: Rosenbaum – volume: 113 start-page: 1206 year: 2015 end-page: 1215 article-title: Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases publication-title: Br J Cancer contributor: fullname: Schaeffer – volume: 483 start-page: 613 year: 2012 end-page: 617 article-title: A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response publication-title: Nature contributor: fullname: Walton – volume: 77 start-page: 2018 year: 2017 end-page: 2028 article-title: Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an Osteopontin-EGFR pathway publication-title: Cancer Res contributor: fullname: Marcar – ident: bibr3-1758834017719829 doi: 10.1038/nature13385 – ident: bibr48-1758834017719829 doi: 10.1016/j.jtho.2016.11.1312 – ident: bibr57-1758834017719829 doi: 10.1038/nature10937 – volume: 55 start-page: 4575 year: 1995 ident: bibr11-1758834017719829 publication-title: Cancer Res contributor: fullname: Rak J – ident: bibr43-1758834017719829 doi: 10.1093/annonc/mdv072 – ident: bibr21-1758834017719829 doi: 10.7314/APJCP.2015.16.10.4439 – ident: bibr41-1758834017719829 doi: 10.1016/j.ccr.2009.03.022 – ident: bibr44-1758834017719829 doi: 10.1016/j.jtho.2016.11.2218 – ident: bibr15-1758834017719829 doi: 10.1200/JCO.2007.12.6953 – ident: bibr45-1758834017719829 doi: 10.1016/S1470-2045(12)70489-8 – ident: bibr1-1758834017719829 doi: 10.1016/S0140-6736(16)00004-0 – ident: bibr59-1758834017719829 doi: 10.1158/1078-0432.CCR-16-2554 – ident: bibr27-1758834017719829 doi: 10.1016/j.jtho.2015.11.010 – ident: bibr5-1758834017719829 doi: 10.1016/j.cell.2012.08.029 – ident: bibr12-1758834017719829 doi: 10.1093/jnci/djr523 – ident: bibr32-1758834017719829 doi: 10.1016/j.lungcan.2012.06.005 – ident: bibr49-1758834017719829 doi: 10.1158/0008-5472.CAN-15-2580 – ident: bibr56-1758834017719829 doi: 10.1158/1078-0432.CCR-14-3112 – ident: bibr50-1758834017719829 doi: 10.1158/1541-7786.MCR-15-0456 – ident: bibr47-1758834017719829 doi: 10.1038/bjc.2015.215 – ident: bibr54-1758834017719829 doi: 10.1038/onc.2015.375 – ident: bibr60-1758834017719829 doi: 10.1016/j.jtho.2016.11.402 – ident: bibr36-1758834017719829 doi: 10.1016/j.critrevonc.2016.12.005 – ident: bibr52-1758834017719829 doi: 10.1101/gad.1950610 – ident: bibr18-1758834017719829 doi: 10.1183/09031936.00097311 – volume: 17 start-page: e1 year: 2016 ident: bibr46-1758834017719829 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2015.12.010 contributor: fullname: Janne PA – ident: bibr53-1758834017719829 doi: 10.1158/2159-8290.CD-14-1236 – ident: bibr31-1758834017719829 doi: 10.1093/annonc/mdq680 – ident: bibr42-1758834017719829 doi: 10.1158/2159-8290.CD-16-0095 – ident: bibr4-1758834017719829 doi: 10.1038/nature07423 – ident: bibr9-1758834017719829 doi: 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E – ident: bibr24-1758834017719829 doi: 10.1038/bjc.2015.327 – ident: bibr13-1758834017719829 doi: 10.18632/oncotarget.4711 – ident: bibr26-1758834017719829 doi: 10.1097/JTO.0000000000000432 – ident: bibr8-1758834017719829 doi: 10.1002/cncr.26311 – ident: bibr25-1758834017719829 doi: 10.1200/JCO.2012.48.1390 – ident: bibr55-1758834017719829 doi: 10.1158/0008-5472.CAN-15-1439 – ident: bibr14-1758834017719829 doi: 10.1200/JCO.2001.19.2.448 – ident: bibr17-1758834017719829 doi: 10.1200/jco.2010.28.15_suppl.7008 – ident: bibr19-1758834017719829 doi: 10.1016/j.lungcan.2013.03.019 – ident: bibr29-1758834017719829 doi: 10.1001/jamaoncol.2016.0405 – volume: 60 start-page: 6750 year: 2000 ident: bibr10-1758834017719829 publication-title: Cancer Res contributor: fullname: Guerrero S – ident: bibr34-1758834017719829 doi: 10.1158/0008-5472.CAN-16-0808 – ident: bibr38-1758834017719829 doi: 10.1038/nrd.2016.139 – ident: bibr7-1758834017719829 doi: 10.1158/1078-0432.CCR-08-0646 – ident: bibr22-1758834017719829 doi: 10.1097/JTO.0000000000000305 – ident: bibr6-1758834017719829 doi: 10.1586/17476348.2016.1115349 – ident: bibr37-1758834017719829 doi: 10.1126/science.aad6204 – ident: bibr39-1758834017719829 doi: 10.1158/2159-8290.CD-15-1105 – ident: bibr51-1758834017719829 doi: 10.1172/JCI82720 – ident: bibr30-1758834017719829 doi: 10.18632/oncotarget.5019 – ident: bibr20-1758834017719829 doi: 10.18632/oncotarget.7080 – ident: bibr58-1758834017719829 doi: 10.1097/JTO.0000000000000687 – volume: 19 start-page: viii61 year: 2008 ident: bibr16-1758834017719829 publication-title: Ann Oncol doi: 10.1093/annonc/mdn503 contributor: fullname: Ma X – ident: bibr33-1758834017719829 doi: 10.1158/1078-0432.CCR-15-2603 – ident: bibr35-1758834017719829 doi: 10.2217/fon.15.273 – ident: bibr40-1758834017719829 doi: 10.1158/2159-8290.CD-16-0092 – ident: bibr2-1758834017719829 doi: 10.1038/nature13898 – ident: bibr28-1758834017719829 doi: 10.1038/bjc.2016.182 – ident: bibr23-1758834017719829 doi: 10.1097/JTO.0000000000000266 |
| SSID | ssj0066460 |
| Score | 2.3159237 |
| SecondaryResourceType | review_article |
| Snippet | KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully... mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed... KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully... |
| SourceID | pubmedcentral proquest crossref pubmed sage |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 589 |
| SubjectTerms | Genomics Immune checkpoint inhibitors K-Ras protein Lung cancer Mutants Mutation Non-small cell lung carcinoma Reviews Small cell lung carcinoma |
| Title | Treating KRAS-mutant NSCLC: latest evidence and clinical consequences |
| URI | https://journals.sagepub.com/doi/full/10.1177/1758834017719829 https://www.ncbi.nlm.nih.gov/pubmed/29081842 https://www.proquest.com/docview/2342366084 https://search.proquest.com/docview/1957767888 https://pubmed.ncbi.nlm.nih.gov/PMC5564881 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NS8MwFH-4HcSL-G11SgQRPMStaZIm3kbdEPxA3A7eSppmOnB1uPX_N-nH3BQvHgolKSS8vCa_x_u9XwDOeSdRUhGFCQk1pkZyLDkz2A-UL1Q4Epq7auTbQfj4Im56TiaH1bUwBWlfJ-Or7H1ylY3fCm7ldKLbNU-s_fQQMcat3_ntBjQsNqxD9HL75ZyWpcEWCGMR0M53brLt2lyTfbexNnGKoUQ6TTdKVo-lX1jzN2VyifdVHEX9LdisMCTqlnPdhjWT7cD6Q5Ul34XesECC2Su6e-4O8CR3NwWjx0F0H12jdwcu58hUt4kilaWoLo9EeolbvQfDfm8Y3eLqugSsKSdzLEZUGZ4wyYRO1Ego-9A0SIQygcVNgoda6FQykhLKmFBcUBZwqqlURksd7EMz-8jMIaBklDq-ZiKpO_B9bkMy3UlNavd1qVQiPLisjRVPS1GM2K90w3_a2INWbc24-j1mMXG6g5x3BPXgbNFtHdtlK1RmPvJZ7EvmlIZshO7BQWn8xWD1qnkQrizL4gMnmr3aY32pEM-ufMeDC7eA31P6a_5H_x7iGDaIwwAFIa0Fzflnbk6gMUvz0yLyPy389gvZqeue |
| link.rule.ids | 230,314,315,729,782,786,794,866,887,27931,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwGP3wAuqL90u9RhDBh2xtmqSJbzInE7chbg--lTTNVHBV3Pb_TXqZTvHFh0JJCkl7kuZ85HwnAGfcT5RURGFCIo2pkRxLzgwOQhUIFQ2E5i4budWLuo_iuulscliVC5OL9nXyUsteh7Xs5TnXVr4Pdb3SidXvOw3GuB13QX0eFu189f0qSC9-wJzTIjnYUmEsQup_7U7WXZkrsvc22ibOM5RI5-pGyezC9Itt_hZNflN-5YvRzdo_X2MdVkv2ia6K6g2YM9kmLHXK_fUtaPZzDpk9obuHqx4eTtwZw6jba7Qbl-jV0dIxMuU5pEhlKaoSK5H-psrehv5Ns99o4fKgBawpJ2MsBlQZnjDJhE7UQCh70TRMhDKhZVyCR1roVDKSEsqYUFxQFnKqqVRGSx3uwEL2lpk9QMkgdUrPRFJHFQJugzntpya1K4JUKhEeXFQfOX4v7DTioHQc_4mNB4cVCnE5sUYxcY6FnPuCenA6rbZTwu1zqMy8TUZxIJnzKLKxvQe7BWjTxiq0PYhm4Jw-4Oy2Z2ssfLntdgmXB-cO-K8u_dX__X83cQLLrX6nHbdvu3cHsEIck8hlbYewMP6YmCOYH6WT43zUfwIuTgBF |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bT9swGP3ERUK8cGfLYGAkhMSDSeLYjs0bKq1AQIVoH_YWObazIdFQ0fb_z86l0KG9bA-RItuSkxw7Pp98fD6AUx7lSiqiMCGpxtRKjiVnFseJioVKC6G5P418M0j7P8R119vkzFN9VaJ9nT9flC-ji_L5V6WtHI902OrEwseHDmPcjbs4HJsiXIZVN2cj0gbq9U-Yc1ofEHZ0GIuERu87lKEv80Xu3kXcxPuGEumd3ShZXJw-Mc7PwskP6q9qQept_serbMFGw0LRVd1kG5ZsuQNrD80--y50hxWXLH-iu6erAR7NfK5h1B907juX6MXT0ymyTT5SpEqD2gOWSH9QZ-_BsNcddm5wk3ABa8rJFIuCKstzJpnQuSqEchc1SS6UTRzzEjzVQhvJiCGUMaG4oCzhVFOprJY62YeV8rW0XwHlhfGKz1xSTxli7oI6HRlr3MoglcpFAOfth87Gta1GFjfO43_iE8Bhi0TWTLBJRrxzIeeRoAGczKvd1PD7Haq0r7NJFkvmvYpcjB_Alxq4eWct4gGkC5DOG3jb7cUaB2Flv91AFsCZB__9kf72_N_-uYtjWHu87mX3t_27A1gnnlBU6rZDWJm-zex3WJ6Y2VE18H8DcqICxQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treating+KRAS-mutant+NSCLC%3A+latest+evidence+and+clinical+consequences&rft.jtitle=Therapeutic+Advances+in+Medical+Oncology&rft.au=Garrido%2C+Pilar&rft.au=Olmedo%2C+Mar%C3%ADa+Eugenia&rft.au=G%C3%B3mez%2C+Ana&rft.au=Paz+Ares%2C+Luis&rft.date=2017-09-01&rft.pub=SAGE+Publications&rft.issn=1758-8359&rft.eissn=1758-8359&rft.volume=9&rft.issue=9&rft.spage=589&rft.epage=597&rft_id=info:doi/10.1177%2F1758834017719829&rft.externalDocID=10.1177_1758834017719829 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-8359&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-8359&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-8359&client=summon |